Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

viking therapeutics inc. - VKTX

VKTX

Close Chg Chg %
51.51 0.02 0.04%

Closed Market

51.53

+0.02 (0.04%)

Volume: 3.64M

Last Updated:

Nov 20, 2024, 4:00 PM EDT

Trade Now

Company Overview: viking therapeutics inc. - VKTX

VKTX Key Data

Open

$52.70

 Day Range

50.40 - 53.04

52 Week Range

11.21 - 99.41

 Market Cap

$5.74B

Shares Outstanding

111.44M

 Public Float

108.05M

Beta

0.99

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.94

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

6.57M

  

VKTX Performance

1 Week
 
 3.89%
 
1 Month
 
 -21.72%
 
3 Months
 
 -20.30%
 
1 Year
 
 319.46%
 
5 Years
 
 617.41%
 

VKTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13
Full Ratings ➔

About viking therapeutics inc. - VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

VKTX At a Glance

Viking Therapeutics, Inc.
9920 Pacific Heights Boulevard
San Diego, California 92121
Phone 1-858-704-4660 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -85,895,000.00
Sector Health Technology Employees 27
Fiscal Year-end 12 / 2024
View SEC Filings

VKTX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.347
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.876
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.001

VKTX Efficiency

Revenue/Employee N/A
Income Per Employee -3,181,296.296
Receivables Turnover N/A
Total Asset Turnover N/A

VKTX Liquidity

Current Ratio 19.191
Quick Ratio 19.191
Cash Ratio 18.922

VKTX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -31.99
Return on Equity -34.794
Return on Total Capital -24.564
Return on Invested Capital -34.639

VKTX Capital Structure

Total Debt to Total Equity 0.362
Total Debt to Total Capital 0.36
Total Debt to Total Assets 0.342
Long-Term Debt to Equity 0.269
Long-Term Debt to Total Capital 0.268
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Viking Therapeutics Inc. - VKTX

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
277.00K 296.00K 291.00K 292.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
277.00K 296.00K 291.00K 292.00K
Depreciation
277.00K 296.00K 291.00K 292.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+6.54% +6.86% -1.69% +0.34%
Gross Income
(277.00K) (296.00K) (291.00K) (292.00K)
Gross Income Growth
-6.54% -6.86% +1.69% -0.34%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
42.38M 55.39M 70.06M 100.53M
Research & Development
31.93M 44.98M 54.23M 63.81M
Other SG&A
10.45M 10.40M 15.83M 36.73M
SGA Growth
+30.71% +30.67% +26.50% +43.49%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(42.66M) (55.68M) (70.36M) (100.83M)
Non Operating Income/Expense
3.27M 710.00K 1.55M 15.02M
Non-Operating Interest Income
3.23M 703.00K 1.59M 15.02M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
106.00K 18.00K 59.00K 88.00K
Interest Expense Growth
-27.40% -83.02% +227.78% +49.15%
Gross Interest Expense
106.00K 18.00K 59.00K 88.00K
Interest Capitalized
- - - -
-
Pretax Income
(39.49M) (54.99M) (68.87M) (85.89M)
Pretax Income Growth
-53.21% -39.23% -25.24% -24.73%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - 12.72M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (12.72M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(39.49M) (54.99M) (68.87M) (85.89M)
Minority Interest Expense
- - - -
-
Net Income
(39.49M) (54.99M) (68.87M) (85.89M)
Net Income Growth
-53.21% -39.23% -25.24% -24.73%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(39.49M) (54.99M) (68.87M) (85.89M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(39.49M) (54.99M) (68.87M) (85.89M)
EPS (Basic)
-0.544 -0.7123 -0.8963 -0.9104
EPS (Basic) Growth
-51.87% -30.94% -25.83% -1.57%
Basic Shares Outstanding
72.60M 77.20M 76.83M 94.35M
EPS (Diluted)
-0.544 -0.7123 -0.8963 -0.9104
EPS (Diluted) Growth
-51.87% -30.94% -25.83% -1.57%
Diluted Shares Outstanding
72.60M 77.20M 76.83M 94.35M
EBITDA
(42.38M) (55.39M) (70.06M) (100.53M)
EBITDA Growth
-30.71% -30.67% -26.50% -43.49%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 109.923
Number of Ratings 13 Current Quarters Estimate -0.283
FY Report Date 12 / 2024 Current Year's Estimate -0.97
Last Quarter’s Earnings -0.22 Median PE on CY Estimate N/A
Year Ago Earnings -0.91 Next Fiscal Year Estimate -1.512
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 3 11 12
Mean Estimate -0.28 -0.31 -0.97 -1.51
High Estimates -0.24 -0.28 -0.92 -1.15
Low Estimate -0.34 -0.37 -1.09 -2.07
Coefficient of Variance -13.27 -15.74 -5.23 -20.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Viking Therapeutics Inc. - VKTX

Date Name Shares Transaction Value
Aug 23, 2024 J. Matthew Singleton Director 10,300 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 23, 2024 Brian Lian President & CEO; Director 2,355,927 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.77 per share 18,305,552.79
Aug 23, 2024 J. Matthew Singleton Director 9,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.72 per share 662,340.00
Aug 23, 2024 J. Matthew Singleton Director 15,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.19 per share 18,088.00
Aug 23, 2024 Brian Lian President & CEO; Director 2,354,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.9 per share 164,609,397.30
Aug 23, 2024 Brian Lian President & CEO; Director 231,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian Lian President & CEO; Director 2,354,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.12 per share 158,062,700.24
Aug 20, 2024 J. Matthew Singleton Director 15,444 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $61.86 per share 955,365.84
Aug 20, 2024 J. Matthew Singleton Director 13,389 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $63.15 per share 845,515.35
Aug 20, 2024 J. Matthew Singleton Director 11,001 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.1 per share 705,164.10
Aug 20, 2024 J. Matthew Singleton Director 9,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.88 per share 616,360.00
Aug 20, 2024 J. Matthew Singleton Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian Lian President & CEO; Director 232,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 187,052 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.71 per share 10,981,822.92
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 190,526 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $56.96 per share 10,852,360.96
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 181,521 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 358,508 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 380,175 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 362,149 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.82 per share 20,939,455.18
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 203,188 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Viking Therapeutics Inc. in the News